Get the Stockscreener App
3.97
2.85%
0.11
Whitehawk Therapeutics Inc stock is traded at $3.97, with a volume of 408.64K.
It is up +2.85% in the last 24 hours and down -1.24% over the past month.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
See More
Previous Close:
$3.86
Open:
$3.88
24h Volume:
408.64K
Relative Volume:
0.92
Market Cap:
$196.33M
Revenue:
$7.15M
Net Income/Loss:
$-20.60M
P/E Ratio:
8.3649
EPS:
0.4746
Net Cash Flow:
$-97.99M
1W Performance:
-5.25%
1M Performance:
-1.24%
6M Performance:
+50.38%
1Y Performance:
+101.52%
1-Day Range:
$3.75
$3.99
1-Week Range:
$3.73
$4.405
52-Week Range:
$1.57
$5.495
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Name
Whitehawk Therapeutics Inc
Sector
Industry
Phone
551-321-2234
Address
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
3.97 | 196.33M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Oppenheimer | Outperform |
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Whitehawk Therapeutics Inc Stock (WHWK) Latest News
WHWK Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Gain on Cost ControlEarnings Cycle Outlook - dars.gov.et
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody Adc Development - marketscreener.com
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development - Business Upturn
WHWKWhitehawk Therapeutics Inc Options - Finviz
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to Russell 2000 Index - marketscreener.com
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to Russell 2000 Value Benchmark - marketscreener.com
Whitehawk Therapeutics, Inc.(NasdaqCM:WHWK) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Whitehawk Therapeutics, Inc.(NasdaqCM:WHWK) added to Russell Small Cap Completeness Index - marketscreener.com
Price to sales forward of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
B. Riley Securities Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $10 - Moomoo
Whitehawk Therapeutics, Inc. Actuals & Estimates (NASDAQ:WHWK) - TradingView
Whitehawk Therapeutics, Inc. Actuals & Estimates (DUS:3350) - TradingView
Price to earnings forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Enterprise value to EBITDA forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
WHWK Initiated Coverage by B. Riley Securities -- Rating Set to Buy - GuruFocus
WHWK Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Whitehawk Therapeutics, Inc. – DUS:3350 - TradingView
B.Riley initiates Whitehawk Therapeutics stock rating at Buy on ADC portfolio - Investing.com Canada
Enterprise value to EBIT forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Price to book forward of Whitehawk Therapeutics, Inc. – DUS:3350 - TradingView
Whitehawk Therapeutics(WHWK) Stock Options Chain | Quotes & News - Moomoo
3 Penny Stocks With At Least $50M Market Cap To Watch - Sahm
Whitehawk Therapeutics (WHWK) director receives 38,040 stock options grant - Stock Titan
Whitehawk Therapeutics (WHWK) director granted 38,040 stock options at $4.16 strike - Stock Titan
Director Richard Maroun receives 38,040 stock options at Whitehawk (WHWK) - Stock Titan
Whitehawk Therapeutics (WHWK) director granted 38,040 stock options at $4.16 - Stock Titan
Whitehawk Therapeutics (WHWK) director receives 38,040 stock options at $4.16 - Stock Titan
Whitehawk Therapeutics (WHWK) director granted options on 38,040 shares - Stock Titan
Whitehawk (WHWK) grants 38,040 stock options to director Aghazadeh - Stock Titan
Whitehawk Shareholders Approve Directors, Pay and Auditor - The Globe and Mail
Whitehawk Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com India
Shareholders of Whitehawk Therapeutics (NASDAQ: WHWK) approve directors, pay and auditor - Stock Titan
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy? - Insider Monkey
[EFFECT] Whitehawk Therapeutics, Inc. SEC Filing - Stock Titan
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockMid-Term Outlook - newsline.com
Whitehawk Therapeutics (WHWK) Slides 5.7%, Eyes Crucial Support Near $3.94Linear Regression - dars.gov.et
Whitehawk Therapeutics Announces $87.5 Million Private Placement Financing - Global Legal Chronicle
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference - marketscreener.com
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 - The AI Journal
WHWK: Selling Stockholder Offers 22.32 Million Shares - GuruFocus
Whitehawk Therapeuticsfiles to offer and resell up to 22.32 million shares of common stock by selling stockholders - marketscreener.com
Whitehawk Therapeutics (WHWK) registers 22.3M shares after $87.5M placement - Stock Titan
Whitehawk CEO to speak at Jefferies 2026 healthcare gathering in NYC - Stock Titan
Whitehawk Therapeutics (WHWK) Edges Lower as Stock Hovers Near Key SupportHigh Volume Node - The Legal Advocate
WHWK: Innovative ADC platform shows strong clinical progress and industry validation for oncology targets - TradingView
WHWK News | WHITEHAWK THERAPEUTICS INC (NASDAQ:WHWK) - ChartMill
WHWK Q1 2026 Earnings: EPS Beat Drives Stock Rally Despite No RevenueGuidance Update - newsline.com
WHWK Q1 2026 Earnings: EPS Beat Drives Positive Sentiment Despite Revenue GapGuidance Update - The Legal Advocate
Whitehawk Therapeutics Inc Stock (WHWK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):